Overview

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborators:
GOG Foundation
Gynecologic Oncology Group (GOG)
Merck Sharp & Dohme Corp.
Myriad Genetic Laboratories, Inc.
Treatments:
Olaparib
Polystyrene sulfonic acid